Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study [0.03%]
关于重型再生障碍性贫血：ELTROMBOPAG加入标准免疫抑制治疗作为一线疗法的长期结果-EBMT-SAAWP RACE随机优势Ⅲ期临床试验
Antonio M Risitano,Simona Iacobelli,Austin Kulasekararaj et al.
Antonio M Risitano et al.
The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2-year analysis of this pro...
Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy [0.03%]
二代测序在强化化疗背景下对急性髓系白血病不同类型患者预后价值的探究
Abiola Bolarinwa,Aref Al-Kali,Hassan B Alkhateeb et al.
Abiola Bolarinwa et al.
We examined the prognostic value of routine NGS data in newly diagnosed acute myeloid leukemia (AML) treated with intensive (7 + 3 backbone) induction, specified by AML subtype. A contemporary (2015-2025) series of 545 Mayo Clinic patients ...
A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST) [0.03%]
评估曲前列尼尔联合常规治疗与单独使用常规治疗对镰状细胞肾病患者肾功能影响的多中心开放标签2期临床研究(STEADFAST研究)
Kenneth I Ataga,Pablo Bartolucci,Santosh L Saraf et al.
Kenneth I Ataga et al.
Martin H Steinberg,David C Rees
Martin H Steinberg
p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases [0.03%]
p53免疫组化是一种可靠的评估TP53等位基因和功能状态的方法
Hong Fang,Joseph D Khoury,Zhenya Tang et al.
Hong Fang et al.
Luspatercept Induces Significant Improvement in Anemia in Dominant Thalassemia Secondary to Heterozygous STEAP3 and Beta-Thalassemia Trait [0.03%]
Luspatercept诱导STEAP3杂合子和β-地中海贫血特征性 dominante地中海贫血患者发生溶血性贫血显著改善
Akhila Arcot Vadivelan,Thomas Coates
Akhila Arcot Vadivelan
POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management [0.03%]
POEMS综合征：2026年诊断、风险分层和管理的更新
Angela Dispenzieri
Angela Dispenzieri
Disease overview: POEMS syndrome is a life-threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions,...
EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion-Dependent Thalassemia [0.03%]
EF2AK1是输血依赖型地中海贫血患者鲁索利替尼抵抗的关键遗传决定因子
Anthony Iscaro,Simona Leoni,Filippo Russo et al.
Anthony Iscaro et al.
Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count [0.03%]
评估镰形细胞病儿童部分脾切除术和全脾切除术的临床疗效及脾功能（标记红血球法）
Alma Al Sibaaie,Abdoulaye Sissoko,Carmen Capito et al.
Alma Al Sibaaie et al.
High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1 [0.03%]
PNH II型中性粒细胞的比例与≥1% PNH克隆患者的血栓形成相关
Orianne Wagner-Ballon,Anne-Catherine Lhoumeau,Anna Raimbault et al.
Orianne Wagner-Ballon et al.
The clinical significance of PNH Type II white blood cells (WBCs) remains unclear. We assessed the relative percentage (rel%) of Type II neutrophils in 355 patients with a PNH clone ≥ 1% on neutrophils enrolled by 33 flow cytometry laborat...